ASSOCIATO

e-mail: voso@med.uniroma2.it
Telefono: +39 06 7259 6280
SSD: MED/15
SC: 06/D3 
Macro-area:
Malattie del sangue, oncologia e reumatologia
Campi di interesse: 
- alterazioni genetiche ed epigenetiche nelle leucemie acute e sindromi mielodisplastiche, de novo e therapy-related
- diagnostica molecolare delle neoplasie ematologiche maligne e malattia minima residua
- protocolli clinici sperimentali per il trattamento della leucemie mieloidi acute e sindromi mielodisplastiche 


 

 Prof. Maria Teresa Voso

---

CURRICULUM VITAE
​
1990             Laurea in Medicina e Chirurgia, Universita’ Cattolica del Sacro Cuore, Roma
1992-1994    Stage di Ricerca presso il Laboratorio del Prof. Daniel G. Tenen, Harvard Medical School, Boston, USA.
1994             Specializzazione in Ematologia, Universita’ Cattolica del Sacro Cuore, Roma
1995             Medico borsista presso l’Istituto di Semeiotica Medica, Universita' Cattolica S. Cuore, Roma
1996-1999    Ricercatore presso l' Unita' Cooperativa Ematologia-Oncologia fra Universita` di Heidelberg e l’ Istituto tedesco per la Ricerca sul Cancro (DKFZ), Heidelberg, Germania
1999-2002    Dirigente Medico presso l’Istituto di Ematologia dell’ Universita’ Cattolica S. Cuore, Roma
2002-2014    Professore Aggregato, Istituto di Ematologia, Universita’ Cattolica Sacro Cuore, Roma, e dirigente medico presso il reparto di Ematologia, Policlinico Gemelli, Roma
2014-            Professore Associato di Malattie del Sangue, Universita’ di Roma Tor Vergata
 
Metrics:       162 peer-reviewed full-text publications, H-index (WOS): 32

Pubblicazioni rilevanti

Voso MT, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol 2017; 28:1547-1553
 
Fabiani E, …& Voso MT Clonal evolution in therapy-related neoplasms. Oncotarget 2017; 8: 12031-12040
 
Cicconi L, .., Voso MT, Mandelli F, Lo-Coco F. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia 2016; 30: 1987-1992
 
 
Della Porta MG, … Voso MT, …Cazzola M. Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol 2016. pii: JCO673616
 
Fianchi L, …, & Voso MT. Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. Am J Hematol 2015; 90: 80-85
 
Voso MT, Lo-Coco F, Fianchi L. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Oncol 2015; 27: 532-539
 
Voso MT, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol 2013; 31: 2671-2677
 
Voso MT, et al Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia 2013; 27: 982-985
 
Voso MT, et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009;15: 5002-7